☆ 4.3 Editorial Material

Myelodysplastic syndromes and bone marrow microenvironment

LEUKEMIA RESEARCH (2011)

期刊

LEUKEMIA RESEARCH

卷 35, 期 11, 页码 1442-1443

出版社

PERGAMON-ELSEVIER SCIENCE LTD

DOI: 10.1016/j.leukres.2011.07.035

关键词

-

类别

Oncology Hematology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Oncology

Nature or Nurture? Role of the Bone Marrow Microenvironment in the Genesis and Maintenance of Myelodysplastic Syndromes

Syed A. Mian, Dominique Bonnet

Summary: Myelodysplastic syndromes (MDS) are a group of bone marrow disorders driven by genetic mutations in stem cells, primarily affecting the elderly but also younger individuals. Current treatments have limited success, with allogeneic HSC transplantation being the only potential cure for <5% of patients. The role of the bone marrow microenvironment in MDS development is still not fully understood, but is increasingly recognized as critical in disease progression.

CANCERS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Genetic Predisposition to Myelodysplastic Syndromes: A Challenge for Adult Hematologists

Elena Crisa, Paola Boggione, Maura Nicolosi, Abdurraouf Mokhtar Mahmoud, Wael Al Essa, Bassel Awikeh, Anna Aspesi, Annalisa Andorno, Renzo Boldorini, Irma Dianzani, Gianluca Gaidano, Andrea Patriarca

Summary: Myelodysplastic syndromes (MDS) arising in the context of inherited bone marrow failure syndromes (IBMFS) present unique challenges in terms of prognosis and treatment, requiring early detection and hematopoietic stem cell transplantation to improve outcomes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Cell Biology

Extracellular Vesicles and MicroRNA in Myelodysplastic Syndromes

Mathieu Meunier, David Laurin, Sophie Park

Summary: The bone marrow niche plays an important role in the development of myelodysplastic syndromes. Mesenchymal stromal cells secrete extracellular vesicles and their miRNA, affecting the fate of hematopoietic stem cells and contributing to leukemogenesis. Extracellular vesicles containing miRNA and proteins can be used as diagnostic and prognostic markers for MDS. Targeting these vesicles or modulating their secretion may offer potential therapeutic directions for MDS.

CELLS (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

EnvIRONmental Aspects in Myelodysplastic Syndrome

Verena Petzer, Igor Theurl, Gunter Weiss, Dominik Wolf

Summary: Systemic iron overload in patients with MDS is multifactorial, mainly due to ineffective erythropoiesis and chronic red blood cell transfusion. Iron homeostasis varies among different MDS subtypes and its role in MDS is increasingly recognized. Genetic alterations, such as mutations in TET2, can lead to disturbances in iron homeostasis and hematopoiesis, highlighting the need for comprehensive understanding and development of future therapies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Medicine, General & Internal

Myelodysplastic syndromes

Huan Li, Fang Hu, Robert Peter Gale, Mikkael A. Sekeres, Yang Liang

Summary: Myelodysplastic syndromes (MDS) are a group of blood cancers characterized by dysregulated hematopoiesis and risk of transformation to acute myeloid leukemia. Prognostic systems can predict survival in MDS patients. Treatment goals differ for low-risk and high-risk MDS, with the aim to improve quality of life and prolong survival, respectively. Hematopoietic cell transplantation can cure MDS, but it is not widely used.

NATURE REVIEWS DISEASE PRIMERS (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Somatic reversion impacts myelodysplastic syndromes and acute myeloid leukemia evolution in the short telomere disorders

Kristen E. Schratz, Valeriya Gaysinskaya, Zoe L. Cosner, Emily A. DeBoy, Zhimin Xiang, Laura Kasch-Semenza, Liliana Florea, Pali D. Shah, Mary Armanios

Summary: The study revealed that patients with germline telomere maintenance defects exhibit diverse somatic adaptive mutations, which may alleviate the telomere crisis that promotes transformation to MDS/AML.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Article Pathology

Bone marrow fibrosis impact on response to azacitidine in myelodysplastic syndromes

Roya Shahidi, Muhajir Mohamed, Archana Sharma, Jessica Heenan, Julia Gardner, Sam Hitchins

Summary: This study aimed to evaluate the impact of azacitidine treatment on MDS patients with bone marrow fibrosis. The study found that patients with fibrotic marrow had shorter overall survival and event-free survival compared to patients without fibrosis. Bone marrow fibrosis was an independent factor affecting overall survival.

PATHOLOGY (2022)

添加到收藏夹

Review Cell Biology

Senescent Mesenchymal Stem Cells in Myelodysplastic Syndrome: Functional Alterations, Molecular Mechanisms, and Therapeutic Strategies

Xiaofang Chen, Ningyu Li, Jianyu Weng, Xin Du

Summary: Myelodysplastic syndrome (MDS) is a group of blood disorders related to dysfunction of hematopoietic stem and progenitor cells. Mesenchymal stem cells (MSCs) in the bone marrow microenvironment play a crucial role in normal hematopoiesis, but their aging and diminished regenerative capacities can contribute to disease progression. Recent studies have provided new insights into the role of MSCs in MDS, suggesting potential targets for treatment.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine

Carlo Pescia, Francesca Boggio, Giorgio Alberto Croci, Ramona Cassin, Marco Barella, Loredana Pettine, Gianluigi Reda, Elena Sabattini, Carlo Finelli, Umberto Gianelli

Summary: Results of the retrospective analysis on 57 high-risk MDS cases treated with azacitidine revealed that the treatment had minimal impact on bone marrow morphology, but led to a slight decrease in CD34+, CD117+, and p53+ cells. Pre-treatment IPSS-R cytogenetic score, lymphocytic infiltrate, and p53+ elements were associated with AML progression, while pre-treatment lymphocytic infiltrate was linked to better therapy response. Post-treatment blast count, lymphocytic infiltrate, and p53+ elements showed significant correlations with prognosis and treatment response.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Quantifying Bone Marrow Fat Fraction and Iron by MRI for Distinguishing Aplastic Anemia from Myelodysplastic Syndromes

Zhaolong Zeng, Xiangzheng Ma, Yifan Guo, Baodong Ye, Maosheng Xu, Wei Wang

Summary: IDEAL-IQ imaging can quantify fat fraction and iron content in bone marrow, aiding in distinguishing between patients with aplastic anemia and myelodysplastic syndrome.

JOURNAL OF MAGNETIC RESONANCE IMAGING (2021)

添加到收藏夹

Article Oncology

Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes - A potential prognostic marker?

Reut Book, Jonathan Ben-Ezra, Chen Glait Santar, Sigi Kay, Galia Stemer, Howard S. Oster, Moshe Mittelman

Summary: Lymphoid aggregates (LA) are occasionally seen in bone marrow biopsies (BMB) of myelodysplastic syndromes (MDS) patients. This study evaluated their incidence and association with prognosis. The results showed that LA are relatively common (24%) in MDS patients and may indicate poor prognosis.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Article Hematology

A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes

Yu-Hung Wang, Hsin-An Hou, Chien-Chin Lin, Yuan-Yeh Kuo, Chi-Yuan Yao, Chia-Lang Hsu, Mei-Hsuan Tseng, Cheng-Hong Tsai, Yen-Ling Peng, Chein-Jun Kao, Wen-Chien Chou, Hwei-Fang Tien

Summary: This study revealed the association between immune cell ratios in the bone marrow of MDS patients and prognosis, with the ICSS scoring system able to stratify patients into high, intermediate, and low-risk groups and independently predict prognosis.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Comparative diagnostic accuracy between simplified and original flow cytometric gating strategies for peripheral blood neutrophil myeloperoxidase expression in ruling out myelodysplastic syndromes

Tatiana Raskovalova, Laura Scheffen, Marie-Christine Jacob, Claire Vettier, Benedicte Bulabois, Gautier Szymanski, Simon Chevalier, Nicolas Gonnet, Sophie Park, Jose Labarere

Summary: This study aimed to simplify the gating strategy for peripheral blood neutrophil myeloperoxidase expression and evaluate its accuracy. The results showed that the simplified strategy performs as well as the original one in ruling out MDS and has the potential to save time and resources.

PLOS ONE (2022)

添加到收藏夹

Article Hematology

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

Michael R. Grunwald, Mei-Jie Zhang, Hany Elmariah, Mariam H. Johnson, Andrew St Martin, Asad Bashey, Minoo Battiwalla, Christopher N. Bredeson, Edward Copelan, Corey S. Cutler, Biju R. George, Vikas Gupta, Christopher Kanakry, Rohtesh S. Mehta, Filippo Milano, Alberto Mussetti, Ryotaro Nakamura, Taiga Nishihori, Wael Saber, Melhem Solh, Daniel J. Weisdorf, Mary Eapen

Summary: This study compared outcomes of HLA-haploidentical relative and HLA-matched unrelated donor hematopoietic cell transplantation in patients with myelodysplastic syndrome. While the haploidentical relative group had higher relapse rates and lower disease-free survival rates, overall survival rates did not differ between donor types. This was due to lower rates of GVHD in haploidentical relative transplants, although mortality associated with chronic GVHD was higher in the unrelated donor group.

BLOOD ADVANCES (2021)

添加到收藏夹

Review Oncology

Germline Predisposition to Myelodysplastic Syndromes

Georgina Gener-Ricos, Yoheved S. Gerstein, Danielle Hammond, Courtney D. DiNardo

Summary: Understanding the biological features and main clinical manifestations of hereditary hematologic malignancies is crucial for identifying and referring patients with myelodysplastic syndrome who may have an inherited predisposition. Individualized genetic counseling and informed treatment decisions, particularly regarding donor selection for hematopoietic stem cell transplant, are important. Future research will enhance our understanding of these disorders and improve management of affected patients and their families.

CANCER JOURNAL (2023)

添加到收藏夹

Review Hematology

The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence

Francesco Passamonti, Giovanni Corrao, Gastone Castellani, Barbara Mora, Giulia Maggioni, Robert Peter Gale, Matteo Giovanni Della Porta

Summary: Most national health-care systems rely on large randomized clinical trials (RCTs) for approving new drugs, but the selection biases, strict criteria, and poor treatment compliance in RCTs may not reflect real-world situations. This discrepancy, along with the limited size of RCTs, often results in the gap between evidence generated in RCTs and its translation to health-care policies. Real-world evidence (RWE) derived from real-world data (RWD) is gaining attention, especially with the help of artificial intelligence (AI), in supporting research and health-care decisions in Hematology.

BLOOD REVIEWS (2022)

添加到收藏夹

Article Medical Laboratory Technology

Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet

Vincent H. J. van der Velden, Frank Preijers, Ulrika Johansson, Theresia M. Westers, Alan Dunlop, Anna Porwit, Marie C. Bene, Peter Valent, Jeroen te Marvelde, Orianne Wagner-Ballon, Uta Oelschlaegel, Leonie Saft, Sharham Kordasti, Robin Ireland, Eline Cremers, Canan Alhan, Carolien Duetz, Willemijn Hobo, Nicolas Chapuis, Michaela Fontenay, Peter Bettelheim, Lisa Eidenshink-Brodersen, Patricia Font, Michael R. Loken, Sergio Matarraz, Kiyoyuki Ogata, Alberto Orfao, Katherina Psarra, Dolores Subira, Denise A. Wells, Matteo G. Della Porta, Kate Burbury, Frauke Bellos, Elisabeth Weiss, Wolfgang Kern, Arjan van de Loosdrecht

Summary: This article reviews the progress of flow cytometry (FCM) in the diagnosis of myelodysplastic syndrome (MDS) in recent years, and provides optimal methods and recommendations for sample processing, antibody panels and fluorochromes, and current hardware technologies. These recommendations will facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients, but further standardization and harmonization are needed.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2023)

添加到收藏夹

Article Medical Laboratory Technology

ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry

Orianne Wagner-Ballon, Peter Bettelheim, Jeroen Lauf, Frauke Bellos, Matteo Della Porta, Erica Travaglino, Dolores Subira, Irene Nuevo Lopez, Sihem Tarfi, Theresia M. Westers, Ulrika Johansson, Katherina Psarra, Serafeim Karathanos, Sergio Matarraz, Enrique Colado, Monali Gupta, Robin Ireland, Wolfgang Kern, Arjan A. Van de Loosdrecht

Summary: This multicenter study demonstrates the robustness of the monocyte assay in distinguishing chronic myelomonocytic leukemia from other causes of monocytosis. It also confirms the possibility of using this assay in bone marrow samples.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2023)

添加到收藏夹

Article Medical Laboratory Technology

Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Arjan A. Loosdrecht, Wolfgang Kern, Anna Porwit, Peter Valent, Sharham Kordasti, Eline Cremers, Canan Alhan, Carolien Duetz, Alan Dunlop, Willemijn Hobo, Frank Preijers, Orianne Wagner-Ballon, Nicolas Chapuis, Michaela Fontenay, Peter Bettelheim, Lisa Eidenschink-Brodersen, Patricia Font, Ulrika Johansson, Michael R. Loken, Jeroen G. Marvelde, Sergio Matarraz, Kiyoyuki Ogata, Uta Oelschlaegel, Alberto Orfao, Katherina Psarra, Dolores Subira, Denise A. Wells, Marie C. Bene, Matteo G. Della Porta, Kate Burbury, Frauke Bellos, Vincent H. J. van der Velden, Theresia M. Westers, Leonie Saft, Robin Ireland

Summary: This article discusses the rationale for including flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group. The WHO 2016 classification acknowledges the contribution of FCM in the diagnosis of MDS and its potential usefulness in prognostication, prediction, therapy evaluation, and patient follow-up.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Mild anemia and 11-to 15-year mortality risk in young-old and old-old: Results from two population-based cohort studies

Alessia A. Galbussera, Sara Mandelli, Stefano Rosso, Roberto Zanetti, Marianna Rossi, Adriano Giacomin, Paolo Detoma, Emma Riva, Mauro Tettamanti, Matteo G. Della Porta, Ugo Lucca

Summary: Findings from this study suggest a significant association between mild anemia and all-cause mortality in the elderly population, with a dose-response relationship between the severity of anemia and mortality risk.

PLOS ONE (2021)

添加到收藏夹

Article Cell & Tissue Engineering

PBX1-directed stem cell transcriptional program drives tumor progression in myeloproliferative neoplasm

Sharon Muggeo, Laura Crisafulli, Paolo Uva, Elena Fontana, Marta Ubezio, Emanuela Morenghi, Federico Simone Colombo, Rosita Rigoni, Clelia Peano, Paolo Vezzoni, Matteo Giovanni Della Porta, Anna Villa, Francesca Ficara

Summary: PBX1 plays a crucial role in regulating the balance between self-renewal and differentiation in hematopoietic stem cells, as well as maintaining proto-oncogenic transcriptional pathways. Studies have shown that lack of PBX1 can prevent the development of MPN caused by the JAK2V617F mutation, suggesting that modulation of the PBX1-driven transcriptional program could be a novel therapeutic approach.

STEM CELL REPORTS (2021)

添加到收藏夹

Article Oncology

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

C. Buske, M. Dreyling, A. Alvarez-Larran, J. Apperley, L. Arcaini, C. Besson, L. Bullinger, P. Corradini, M. Giovanni Della Porta, M. Dimopoulos, S. D'Sa, H. T. Eich, R. Foa, P. Ghia, M. G. da Silva, J. Gribben, R. Hajek, C. Harrison, M. Heuser, B. Kiesewetter, J. J. Kiladjian, N. Kroeger, P. Moreau, J. R. Passweg, F. Peyvandi, D. Rea, J-M Ribera, T. Robak, J. F. San-Miguel, V Santini, G. Sanz, P. Sonneveld, M. Von Lilienfeld-Toal, C. Wendtner, G. Pentheroudakis, F. Passamonti

Summary: This study aims to discuss the impact of the COVID-19 pandemic on the management of patients with hematological malignancies and provide expert advice. Through international collaboration and consensus meetings, consensus guidelines were developed to guide clinical decision making for patients.

ESMO OPEN (2022)

添加到收藏夹

Article Hematology

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Carlo Visco, Luigi Marcheselli, Roberto Mina, Marianna Sassone, Anna Guidetti, Domenico Penna, Chiara Cattaneo, Valentina Bonuomo, Alessandro Busca, Andres Jose Maria Ferreri, Riccardo Bruna, Luigi Petrucci, Roberto Cairoli, Marco Salvini, Lorenza Bertu, Marco Ladetto, Sofia Pilerci, Antonello Pinto, Safaa Ramadan, Francesco Marchesi, Michele Cavo, Luca Arcaini, Elisa Coviello, Alessandra Romano, Pellegrino Musto, Massimo Massaia, Nicola Fracchiolla, Monia Marchetti, Annamaria Scattolin, Maria Chiara Tisi, Antonio Cuneo, Matteo Della Porta, Livio Trentin, Marco Turrini, Filippo Gherlinzoni, Agostino Tafuri, Sara Galimberti, Monica Bocchia, Valeria Cardinali, Daniela Cilloni, Alessandro Corso, Daniele Armiento, Luigi Rigacci, Elettra Ortu La Barbera, Carlo Gambacorti-Passerini, Giuseppe Visani, Daniele Vallisa, Adriano Venditti, Carmine Selleri, Annarita Conconi, Patrizia Tosi, Francesco Lanza, Anna Candoni, Mauro Krampera, Paolo Corradini, Francesco Passamonti, Francesco Merli

Summary: This study investigated the clinical behavior and clinical parameters of lymphoma patients with COVID-19, with the aim of identifying predictors of death. The results showed that lymphoma patients had poor outcomes when diagnosed with COVID-19, but treatment for lymphoma did not impact survival. The study also identified four easy-to-use factors associated with the risk of death.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

Margherita Maffioli, Barbara Mora, Somedeb Ball, Alessandra Iurlo, Elena Maria Elli, Maria Chiara Finazzi, Nicola Polverelli, Elisa Rumi, Marianna Caramella, Maria Cristina Carraro, Mariella D'Adda, Alfredo Molteni, Cinzia Sissa, Francesca Lunghi, Alessandro Vismara, Marta Ubezio, Anna Guidetti, Sabrina Caberlon, Michela Anghilieri, Rami Komrokji, Daniele Cattaneo, Matteo Giovanni Della Porta, Toni Giorgino, Lorenza Bertu, Marco Brociner, Andrew Kuykendall, Francesco Passamonti

Summary: Ruxolitinib is commonly used in the treatment of myelofibrosis, but many patients lose response over time. This study identified predictors of survival and developed a prognostic model to identify patients who may benefit from a treatment switch.

BLOOD ADVANCES (2022)

添加到收藏夹

Review Oncology

Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: It's more a matter of burden or more of exposure to toxic iron form?

Federica Pilo, Daniela Cilloni, Matteo Giovanni Della Porta, Gian Luca Forni, Alberto Piperno, Valeria Santini, Emanuele Angelucci

Summary: This article reviews the recent understanding of the concept of exposure to free iron-mediated damage and emphasizes the importance of reducing organ exposure to ROS in order to prevent or delay organ damage.

LEUKEMIA RESEARCH (2022)

添加到收藏夹

Article Oncology

Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV

Patrizia Zappasodi, Chiara Cattaneo, Virginia Valeria Ferretti, Roberto Mina, Andres Jose Maria Ferreri, Francesco Merli, Margherita Oberti, Mauro Krampera, Alessandra Romano, Caterina Zerbi, Jacqueline Ferrari, Michele Cavo, Marco Salvini, Lorenza Bertu, Nicola Stefano Fracchiolla, Francesco Marchesi, Massimo Massaia, Vincenzo Marasco, Roberto Cairoli, Anna Maria Scattolin, Alessandro Maria Vannucchi, Carlo Gambacorti-Passerini, Pellegrino Musto, Filippo Gherlinzoni, Antonio Cuneo, Antonello Pinto, Livio Trentin, Monica Bocchia, Sara Galimberti, Elisa Coviello, Maria Chiara Tisi, Alessandro Morotti, Brunangelo Falini, Mauro Turrini, Agostino Tafuri, Atto Billio, Massimo Gentile, Roberto Massimo Lemoli, Adriano Venditti, Matteo Giovanni Della Porta, Francesco Lanza, Luigi Rigacci, Patrizia Tosi, Sara Mohamed, Alessandro Corso, Mario Luppi, Nicola Giuliani, Alessandro Busca, Livio Pagano, Raffaele Bruno, Paolo Antonio Grossi, Paolo Corradini, Francesco Passamonti, Luca Arcaini

Summary: This study analyzed the impact of secondary infections in patients with hematological malignancies and COVID-19. It found that patients with secondary infections were older, had more comorbidities, and had worse outcomes from COVID-19.

HEMATOLOGICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients

Barbara Mora, Paola Guglielmelli, Andrew Kuykendall, Elisa Rumi, Margherita Maffioli, Francesca Palandri, Valerio De Stefano, Marianna Caramella, Silvia Salmoiraghi, Jean-Jacques Kiladjian, Jason Gotlib, Alessandra Iurlo, Francisco Cervantes, Marco Ruggeri, Richard T. Silver, Francesco Albano, Giulia Benevolo, David M. Ross, Matteo G. Della Porta, Timothy Devos, Giada Rotunno, Rami S. Komrokji, Ilaria C. Casetti, Michele Merli, Marco Brociner, Domenica Caramazza, Giuseppe Auteri, Tiziano Barbui, Daniele Cattaneo, Lorenza Bertu, Luca Arcaini, Alessandro M. Vannucchi, Francesco Passamonti

Summary: Patients with Philadelphia-negative myeloproliferative neoplasms are at high risk of thrombotic events, and cytoreductive therapy can reduce the risk of thrombosis in patients with secondary myelofibrosis.

LEUKEMIA (2022)

添加到收藏夹

Review Oncology

CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature

Vincenzo Guastafierro, Marta Ubezio, Nicla Manes, Chiara Milanesi, Matteo Della Porta, Arturo Bonometti

Summary: Chronic myelomonocytic leukemia (CMML) is a rare entity characterized by persistent peripheral blood monocytosis, hypercellular bone marrow, and dysplasia. This case report highlights a rare CSF3R-mutated CMML, which shares similarities with both CMML and CNL at clinical, pathological, and molecular levels. The diagnostic and therapeutic challenges posed by this unique mutation in CMML are emphasized.

LEUKEMIA & LYMPHOMA (2023)

添加到收藏夹

Review Imaging Science & Photographic Technology

Generative Adversarial Networks in Brain Imaging: A Narrative Review

Maria Elena Laino, Pierandrea Cancian, Letterio Salvatore Politi, Matteo Giovanni Della Porta, Luca Saba, Victor Savevski

Summary: Artificial intelligence is expected to have a significant impact on radiology, particularly in brain imaging. Generative Adversarial Networks (GANs) have been proposed as an exciting application of deep learning in this field, enabling various processes such as image synthesis, reconstruction, and data augmentation.

JOURNAL OF IMAGING (2022)

添加到收藏夹

Article Hematology

Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project

Matteo Franchi, Claudia Vener, Donatella Garau, Ursula Kirchmayer, Mirko Di Martino, Marilena Romero, Ilenia De Carlo, Salvatore Scondotto, Chiara Stival, Matteo Giovanni Della Porta, Francesco Passamonti, Giovanni Corrao

Summary: In a large cohort of non-transplant MM patients treated outside the experimental setting, first-line treatment with bortezomib-based therapy showed a favorable effectiveness and cost-effectiveness profile compared to conventional chemotherapy.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2021)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.